Trial Profile
Double-blind, placebo-controlled, randomized, parallel-group Phase II study in subjects with relapsing forms of multiple sclerosis (MS) to evaluate the safety, tolerability, and effects of two doses of CDP323 over 24 weeks with a rater-blind MRI follow-up over 12 weeks
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs CDP 323 (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors UCB
- 23 Jun 2012 Primary endpoint (Drug concentration) added as reported by European Clinical Trials Database record.
- 23 Jun 2012 Inclusion and exclusion criteria amended as reported by European Clinical Trials Database record.
- 23 Jun 2012 Official Title amended as reported by European Clinical Trials Database record.